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Expression of the gene encoding human inosine- 5*-
monophosphate dehydrogenase (IMPDH) type II, an en-
zyme catalyzing the rate-limiting step in the generation
of guanine nucleotides, is increased more than 10-fold in
activated peripheral blood T lymphocytes and is re-
quired for T cell activation. We have examined the 5*-
regulatory sequences that are important for the tran-
scriptional regulation of this gene in T cells. DNase I
mapping of genomic DNA identified a hypersensitive
element near the transcription initiation site. Fine map-
ping by in vivo footprinting demonstrated five tran-
scription factor binding sites that are occupied in both
resting and activated peripheral blood T lymphocytes;
these are tandem CRE motifs, a Sp1 site, an overlapping
Egr-1/Sp1 site, and a novel palindromic octamer se-
quence (POS). The tandem CRE and POS sites are of
major functional importance as judged by mutational
and electrophoretic mobility shift analyses. These data
provide evidence that expression of the human IMPDH
type II gene is predominantly regulated by the nuclear
factors ATF-2 and an as yet unidentified POS-binding
protein. Additional major protein-DNA interactions do
not occur within the promoter region after T lympho-
cyte activation, indicating a requirement for additional
protein-protein interactions and/or post-translational
modifications of pre-bound transcription factors to ac-
count for the observed increase in IMPDH type II gene
expression.
Cellular inosine-59-monophosphate dehydrogenase (IM-
PDH,1 EC 1.1.1.205) enzymatic activity is the result of the
expression of two independent genes, IMPDH type I and type
II, that encode proteins with identical catalytic activities (1–5).
IMPDH catalyzes the NAD-dependent oxidation of inosine 59-
monophosphate to xanthosine 59-monophosphate in the de novo
synthesis of guanine deoxy- and ribonucleotides required for
DNA and RNA biosynthesis, respectively. Increased IMPDH
activity has been correlated with both cellular proliferation and
malignant transformation (6, 7). The IMPDH type II mRNA
transcript is the predominant of the two species in most normal
cells and tissues and is expressed at significantly increased
levels in replicating and neoplastic cells and upon T lympho-
cyte activation (8–11). The pivotal role that this increase in
enzymatic activity and concomitant increase in guanine nucle-
otide biosynthesis plays in T lymphocyte activation is illus-
trated by the ability of selective IMPDH inhibitors, such as
mycophenolic acid and mizoribine, to abrogate T lymphocyte
responses both in vitro and in vivo (12–14). These agents also
induce cell differentiation in a number of cultured leukemic cell
lines (15–18) and in primary leukemic cells from patients with
blast crisis of chronic myelocytic leukemia (13). Such inhibitors
are in current clinical use as immunosuppressive drugs in the
prevention of allograft rejection (19, 20).
We have recently shown that the human IMPDH type II
gene located on chromosome 3p21.2 3 24.2 (3) is approxi-
mately 5.8 kb in length and consists of 14 exons varying in size
from 49 to 207 bp (21). The transcription initiation site was
located by primer extension analysis and RNase protection to a
position 50 bp upstream of the translation initiation codon. The
59-flanking region of the type II gene previously identified as
containing promoter activity consists of 463 base pairs up-
stream of and including the translation initiation site. Trans-
fection of a chloramphenicol acetyltransferase reporter gene
construct containing this DNA sequence into human peripheral
blood T lymphocytes resulted in a significant increase in ex-
pression over base line after activation of the cells with phorbol
ester and ionomycin, suggesting that it contains the regulatory
elements necessary for the activation associated increase in
gene expression. In vitro DNase I footprinting analysis using
Jurkat T cell nuclear extract identified four protected regions
in the promoter that coincided with consensus transcription
factor binding sites including AP2, tandem CREs, an overlap-
ping Egr-1/Sp1 site, and an Nm23 motif, but the functional
significance of these sites remained a subject of speculation
(21).
In view of the important role of IMPDH type II gene expres-
sion in both T lymphocyte activation and neoplasia, we have
investigated the molecular mechanisms governing the regula-
tion of this gene in the most physiologically relevant system,
human primary T lymphocytes. To identify the specific ele-
ments required for differential expression at the transcrip-
tional level, we have asked whether differential occupancy of
specific transcription factor binding sites occurs in vivo as a
consequence of T lymphocyte activation and have further ex-
amined the functional significance of these sites.
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MATERIALS AND METHODS
Isolation of Peripheral Blood T Lymphocytes—Buffy coats from nor-
mal donors were obtained from the American Red Cross (Charlotte,
NC), and the mononuclear cells were isolated by density gradient cen-
trifugation using Histopaque-1077 (Sigma). Cells at the interface were
removed, washed three times with phosphate-buffered saline (PBS)
(350 3 g, 37 °C), and resuspended in RPMI 1640 medium containing
10% heat-inactivated fetal calf serum (Hyclone Laboratories, Logan,
UT). Monocytes were depleted by adherence and B lymphocytes by
maintaining cells in culture for 3 days prior to stimulation. Flow cyto-
metric analysis of the isolated T lymphocytes with an anti-CD21
marker revealed a greater than 95% enrichment of CD21 T cells.
Cellular [3H]thymidine incorporation into DNA from resting and acti-
vated T lymphocytes was determined as a measure of proliferative
activity.
mRNA Stability—Peripheral blood T lymphocytes (107 cells/sample)
from a single donor were stimulated consecutively with 1 mg/ml PHA
(Sigma) and 10 units/ml IL-2 (Sigma) for 48, 24, 3, and 0 h. At time 0 h,
the cells were treated with 5 mg/ml actinomycin D (Sigma) for 0, 2, 4, 6,
8, and 10 h. Total cellular RNA was isolated with Tri-Reagent (MRC,
Cincinnati, OH), dissolved in Formazol (MRC), and 5 mg analyzed on
denaturing formaldehyde-agarose gels. The RNA was transferred to
ZetaProbe GT membranes (Bio-Rad) using Northern transfer solution
(MRC). Membranes were prehybridized and hybridized according to
and using the high efficiency hybridization system (MRC) and sequen-
tially probed with random-primed [a-32P]dCTP-labeled full-length IM-
PDH type II cDNA (provided by Dr. F. Collart, Argonne National
Laboratory, Argonne, IL) and a [g-32P]ATP end-labeled human 28 S
rRNA-specific oligonucleotide (59-AAAACGATCAGAGTAGTGGTATT-
TCACCG-39)(CLONTECH, Palo Alto, CA). mRNA levels were quanti-
tated with a PhosphorImager (Molecular Dynamics, Sunnyvale, CA)
after a 3-day exposure for the IMPDH type II probe and a 4.5-h expo-
sure for the 28 S rRNA probe. IMPDH type II mRNA levels were
normalized for 28 S rRNA loading, and the values were plotted on a
logarithmic scale.
DNase I-hypersensitive Site Analysis—The locations of DNase I-hy-
persensitive sites were mapped according to the method of Wu (22).
Briefly, nuclei from 108 Jurkat T E6–1 cells (23) were swollen on ice for
5 min by incubation in 50 ml of hypotonic reticulocyte standard buffer
(10 mM Tris, pH 7.4, 10 mM NaCl, 5 mM MgCl2), isolated by centrifu-
gation (500 3 g, 4 °C, 5 min), and subsequently lysed (4 °C, 5 min) in 25
ml of reticulocyte standard buffer containing 0.5% Nonidet P-40. The
nuclei were isolated by centrifugation (500 3 g, 4 °C, 5 min), resus-
pended in 0.5 ml of DNase I digestion buffer (10 mM HEPES, pH 7.5, 10
mM NaCl, 5 mM MgCl2, 1 mM CaCl2), and digested with various con-
centrations of DNase I (0, 0.05, 0.1, 0.25, 0.5, 0.75, 1, and 2 mg/ml)
(Worthington) for 15 min at 37 °C. The reaction was terminated with
the addition of freshly prepared proteinase K (10 mg/ml) (Sigma) in stop
solution (20 mM Tris-HCl, pH 7.4, 600 mM NaCl, 5 mM EDTA, 1% SDS).
Following overnight incubation at 37 °C, the DNA was extracted twice
with phenol/chloroform, once with chloroform and subsequently precip-
itated with isopropyl alcohol in the presence of 2.5 M NH4OAc. The DNA
(15 mg) was digested overnight with SacI and separated on a 1% agarose
gel. The gel was denatured in 0.5 M NaOH for 1 h, neutralized in 1 M
Tris-HCl, pH 7.5, 1.5 M NaCl for 1 h, and transferred overnight onto
ZetaProbe GT membrane (Bio-Rad). The blots were prehybridized (50%
formamide, 0.12 M Na2HPO4, pH 7.2, 0.25 M NaCl, 7% SDS) for 1 h at
42 °C and hybridized overnight in high efficiency hybridization system
(MRC) with [g-32P]ATP end-labeled probes obtained by PCR of exon 5
(forward primer, 59-TTCATCACAGACCCTGTGGTCCTC-39; reverse
primer, 59-CCAAGAAACAGTCATGTTCCTCCT-39) and exons 6 and 7
(forward primer, 59-AAGACTTGGTGGTAGCCCCTGC-39; reverse
primer, 59-ACTTGTCATCCTCATGAGTGCC-39), washed, and autora-
diographed for 4 and 2 days, respectively.
In Vivo Footprinting—In vivo methylation and isolation of DNA from
T lymphocytes and Jurkat T E6–1 cells were performed as described
previously (24). Peripheral blood T lymphocytes were cultured in the
absence or presence of PHA-L (6 mg/ml) and IL-2 (10 units/ml) for 24,
48, and 72 h, respectively. Jurkat E6–1 cells were cultured in the
absence or presence of PMA (10 ng/ml) for 3 h. IL-2 receptor expression
in resting and activated T lymphocytes was determined by flow cytom-
etry using the CD25 antibody M-A251 (Pharmingen, San Diego, CA).
Cells (108) were harvested by centrifugation, resuspended in 10 ml of
RPMI 1640, and methylated using 1 ml/ml dimethyl sulfate for 5 min at
37 °C. The reaction was terminated by the addition of ice-cold PBS
containing 60 mM Tris, pH 7.5. The cells were recovered by centrifuga-
tion (900 3 g, 4 °C, 2 min), washed in PBS/Tris, and lysed in 0.5 ml of
lysis buffer (60 mM Tris, pH 7.5, 100 mM EDTA, 0.1% SDS, 500 mg/ml
proteinase K) for 4 h at room temperature. Genomic DNA was extracted
by the addition of 1 ml of phenol followed by an equal volume of
chloroform:isoamyl alcohol (24:1). The aqueous phase was removed and
extracted with chloroform:isoamyl alcohol. The DNA was spooled in the
presence of 1⁄10 volume of 3 M NaOAc and 2.5 volumes of ethanol,
resuspended in 1 ml of 10 mM Tris, pH 8, 0.1 mM EDTA, incubated
overnight at 4 °C, and digested with 100 units of HindIII restriction
enzyme for 4 h at 37 °C. Digests stored overnight (4 °C) were extracted
as described above, resuspended in 200 ml of 10 mM Tris, pH 8, 0.1 mM
EDTA, and stored at 4 °C. Control DNA was methylated in vitro with 1
ml of dimethyl sulfate for 15 s. The reaction was terminated by the
addition of 50 ml of 1.5 M NaOAc, pH 7, 1 M b-mercaptoethanol, 100
mg/ml tRNA, and the DNA was precipitated with 750 ml of ethanol.
Piperidine diluted 1:10 (200 ml) was added to the pellet, and the sam-
ples were incubated at 90 °C for 30 min, frozen, and lyophilized. Two
additional lyophilizations were performed from 100 and 50 ml of dis-
tilled H2O volumes, respectively, and the DNA was diluted to 1.5 mg/ml
in distilled H2O. The ligation-mediated PCR was performed as de-
scribed previously (25) with modifications (26). Two primer sets were
used to encompass the IMPDH type II 59-flanking region (bp 2267 to
214) upper strand: P1(2333), 59-TTTTGGGGAGGAGCCCG-39 (Tm 5
60 °C); P2(2318), 59-CGGCGGGACAGTAGAAGTAAACCCTTGC-39
(Tm 5 65 °C); P3(2318), 59-CGGCGGGACAGTAGAAGTAAACCCTT-
GCCTG-39 (Tm 5 67 °C), and lower strand: P1(83), 59-TCTCCGCAGT-
TGAAGAGC-39 (Tm 5 58 °C); P2(29), 59-GTGCCCCCACTAATCAGG-
TAGTCGGC-39 (Tm 5 65 °C); P3(29), 59-GTGCCCCCACTAATCAGGT-
AGTCGGCCATG-39 (Tm 5 67 °C).
Transient Transfections—Chloramphenicol acetyltransferase (CAT)
reporter constructs (10 mg) were transfected into 107 exponentially
growing Jurkat T E6-1 cells. Promoter-deletion CAT constructs were
transfected in equimolar ratios adjusted for promoter insert size. Cells
were maintained in RPMI 1640 medium supplemented with 2 mM
L-glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin, and 10%
fetal calf serum (Hyclone Laboratories) and cultured at 37 °C in a
humidified atmosphere in the presence of 5% CO2. Electroporations
were performed at room temperature in the presence of RPMI 1640
lacking Ca21 using a Bio-Rad Gene Pulser with settings at 250 V/960
microfarads. The transfected cells were cultured for 48 h, harvested,
washed three times with PBS, resuspended in 150 ml of 0.25 M Tris-HCl,
pH 8.0, and extracted with three cycles of freeze-thawing. Aliquots were
heated to 60 °C for 10 min and centrifuged at 16,000 3 g for 10 min. The
supernatants were assayed with 0.1 mCi of [14C]chloramphenicol and 25
mg of n-butyryl coenzyme A for 2 h, extracted with xylenes according to
the Promega CAT Enzyme Assay System (Madison, WI), and analyzed
by liquid scintillation counting. Protein concentrations were deter-
mined with the Micro BCA Protein Assay Reagent Kit (Pierce).
Nuclear Extracts—Nuclear extracts from control and PMA (10 ng/
ml)-treated Jurkat T E6–1 cells and peripheral blood T lymphocytes
cultured in the absence or presence of PHA-L (1 mg/ml) (Sigma) and
IL-2 (10 units/ml) (Life Technologies, Inc.) for 3, 6, 12, and 24 h,
respectively, were prepared according to the method of Dignam et al.
(27) with modifications (28). The nuclear extraction was performed at
4 °C. Cells were washed twice with 50 ml of PBS and resuspended in 5
pellet volumes of buffer A (10 mM HEPES, pH 7.9, 0.75 mM spermidine,
0.15 mM spermine, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT,
1 mM PMSF), incubated for 5 min, homogenized with a B pestle in a
Dounce homogenizer, and centrifuged at 30,000 3 g for 30 s. The nuclei
were resuspended in 1 pellet volume of buffer C (20 mM HEPES, pH 7.9,
0.75 mM spermidine, 0.15 mM spermine, 0.2 mM EDTA, 2 mM EGTA, 2
mM DTT, 1 mM PMSF, 20% glycerol), the NaCl concentration adjusted
to 0.4 M, the nuclei agitated for 20 min, and the nuclear extract subse-
quently obtained by pelleting the nuclei at 30,000 3 g for 60 min.
Control Jurkat T cell nuclear extract was subsequently dialyzed 2 3 90
min in buffer D (20 mM HEPES, pH 7.9, 12.5 mM MgCl2, 100 mM KCl,
0.2 mM EDTA, 0.2 mM EGTA, 2 mM DTT, 1 mM PMSF, 17% glycerol).
The extracts were aliquoted and stored at 270 °C.
Electrophoretic Mobility Shift Assays—Wild-type and mutant dou-
ble-stranded oligonucleotides were generated by annealing complemen-
tary single-stranded oligonucleotides and either labeled by fill-in using
Klenow DNA polymerase or kinasing using T4 polynucleotide kinase
(Promega). Labeled double-stranded oligonucleotides were purified on 1
ml of Sephadex G-50 (Sigma) columns. The flow-through was precipi-
tated with 1⁄10 volume of 3 M NaOAc and 3 volumes of ethanol, washed
with 95% ethanol, and resuspended at 20,000 cpm/ml. For competition
experiments, unlabeled wild-type and mutant oligonucleotides were
prepared by using unlabeled deoxynucleotides for fill-in and precipi-
tated as described above. One ml of probe (approximately 0.1 ng of DNA)
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was incubated with 8 mg of nuclear extract in the presence of 20 mM
HEPES, pH 7.5, 0.5 mM DTT, 1 mM EDTA, 2 mM MgCl2, 50 mM KCl,
12% glycerol, and 2 mg of poly(dI-dC) (Sigma). Reactions were preincu-
bated on ice for 10 min in the presence of competitor or 30–60 min in
the presence of antibodies. Probe was added to the mixture, and the
reaction was incubated at room temperature for 20 min. The protein-
DNA complexes were resolved on native 4% polyacrylamide (30:1, ac-
rylamide:bisacrylamide), 0.5 3 Tris/borate/EDTA minigels at 100 V,
dried, and autoradiographed. Electrophoretic mobility shift analysis
(EMSA) supershift experiments were performed with 1 mg of each
antibody as follows: the ATF-1 antibody (sc-270X) that cross-reacts with
CREB-1 and CREM-1, and the specific antibodies ATF-1 (sc-241X),
ATF-2 (sc-187X), CREB-1 (sc-186X), CREM-1 (sc-440X), Sp1 (sc-59X),
and Egr-1 (sc-110X) (Santa Cruz Biotechnology, Santa Cruz, CA).
Deletion Constructs—Promoter fragments were subcloned into the
Klenow DNA polymerase filled-in HindIII site of pCATBasic unless
stated otherwise. A 466-bp construct containing the 59-flanking region
extending from an EcoRI to an NcoI site at the ATG initiation codon in
the first exon (bp 2463 to 13) was obtained by isolating the region from
pGEM466 (21) using the multiple cloning region (MCR) HindIII/XbaI
sites and subcloning the fragment into the identical sites of pCATBasic.
To remove the translation initiation codon, a 461-bp promoter fragment
was released by a HindIII/MscI digest, the insert HindIII site filled in,
and the fragment subcloned into pCATBasic in the 59 3 39 orientation
(pCATBasic461). A pCATBasic1027 promoter construct was obtained
by cloning a 1029-bp NcoI 59 fragment containing the translation initi-
ation site into pCATBasic in 59 3 39 orientation and removing the
translation initiation site by replacing the 39 region with the SphI
fragment (bp 2199 to MCR) obtained from pCATBasic461. The SphI
fragment was subcloned into the pCATBasic MCR SphI in 59 3 39
orientation to obtain pCATBasic197. The SphI fragment was digested
with NlaIV (bp 2143), treated with mung bean nuclease (New England
Biolabs, Beverly, MA), and the 39 region subcloned into pCATBasic to
yield the 59 3 39 construct pCATBasic141. The constructs were se-
quenced, and the amount of transfected DNA was normalized for pro-
moter insert size.
Site-directed Mutagenesis—Transcription factor binding sites in the
promoter region were mutagenized according to the method of Jones et
al. (29). Primary and secondary PCR reactions were performed using
Pfu polymerase (Stratagene, La Jolla, CA). The template for the site-
directed mutagenesis consisted of the 4.8-kb genomic clone contained in
pGEM7Zf(1) (21). The 22-bp forward primer 59-TGGGCTGACA-
GACTTTGCTGAC-39 annealing to position 2716 to 2695 bp and the
26-bp reverse complementary primer 59-GTTGAAGAGCTGCTGTGCT-
GTGAGTC-39 annealing to position 149 to 175 bp relative to the
translation initiation site were used as the flanking primers for the
PCR-mediated mutagenesis. Sequences of oligonucleotides used for the
mutagenesis are shown in Table I. The mutated 461-bp promoter frag-
ments were released with an EcoRI/MscI digest, filled-in with Klenow
DNA polymerase, gel-purified, subcloned into the filled-in HindIII site
of pCATBasic, and sequenced. A promoter construct containing both
CRE site mutations was generated and assayed in transient transfec-
tion assays. This double mutation resulted in a single cytosine-bp
deletion in the CRE(B) site.
RESULTS
IMPDH Type II mRNA Stability in Resting and Activated T
Lymphocytes—To determine whether differential mRNA sta-
bility could play a role in the increase in IMPDH type II
expression, mRNA levels were quantitated in resting and acti-
vated T lymphocytes following actinomycin D treatment. IM-
PDH type II mRNA levels increased in a time-dependent fash-
ion upon T lymphocyte stimulation with PHA and IL-2 (Fig.
1A). Levels increased 2-, 19-, and 15-fold over those in unstimu-
lated T lymphocytes after 3, 24, and 48 h of stimulation, re-
spectively, in the absence of actinomycin D (time 0 h). The rate
of decrease in IMPDH type II mRNA after actinomycin D
treatment was similar in resting and activated T lymphocytes
with t1⁄2 values of 6, 4.5, 5, and 5 h at 0, 3, 24, and 48 h of
stimulation, respectively (Fig. 1B). The lack of an increase in
mRNA stability in activated T lymphocytes confirms our pre-
vious studies implicating a primary role for transcriptional
regulation in the increased expression of this gene (21). In
addition, in a separate experiment, we quantitated the increase
in IMPDH type II mRNA by Northern blot analysis in isolated
FIG. 1. IMPDH type II mRNA half-
life determinations in resting and ac-
tivated T lymphocytes. A, resting (0 h)
and activated (3, 24, and 48 h) peripheral
blood T lymphocytes were treated with 5
mg/ml actinomycin D for the indicated
time intervals. RNA was isolated, 5 mg
run on denaturing gels, blotted onto nylon
membrane, and sequentially probed with
IMPDH type II cDNA and a 28 S rRNA-
specific oligonucleotide. B, IMPDH type II
mRNA and 28 S rRNA levels were quan-
titated using a Molecular Dynamics Phos-
phorImager and IMPDH type II mRNA
expression normalized for 28 S rRNA ex-
pression. [3H]Thymidine uptake was in-
creased 15-fold in the activated T lympho-
cytes after 48 h of stimulation.
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CD4 and CD8 T lymphocyte subpopulations. IMPDH type II
mRNA levels increased 11-fold in CD4 and 5-fold in CD8 cells
after 24 h, indicating up-regulation of gene expression on acti-
vation of both lymphocyte populations (data not shown).
Mapping of DNase I-hypersensitive Elements at the IMPDH
Type II Locus—To define cis-acting regulatory regions in the
IMPDH type II gene, the chromatin structure of the gene and
surrounding regions encompassing approximately 11 kb were
mapped for sites that are hypersensitive to digestion with
DNase I (Fig. 2A). An exon 5 probe corresponding to the 39 end
of a 4.8-kb SacI genomic fragment revealed a DNase I-hyper-
sensitive element (I) that localizes to the 59-flanking region of
the IMPDH type II gene previously demonstrated to contain
promoter activity and a cluster of potential transcription factor
binding motifs that include AP2, CRE, Egr-1, Nm23, and Sp1
(21) (Fig. 2, A and B). An exon 6 probe corresponding to the 59
end of a 6.4-kb SacI genomic fragment identified a region
containing two hypersensitive elements (II and III) approxi-
mately 0.5 kb apart and located 2.5 and 3.0 kb 39 to the end of
the coding region (Fig. 2, A and C). Further sequencing of this
region demonstrated sequence identities with several cDNA
sequences (W01132, D61550, D81230, and N27626) in Gen-
Bank. Alignment of these overlapping cDNA fragments with
the region 39 to the IMPDH type II gene identified a 2-kb gene
that is oriented tail-to-tail with respect to the IMPDH type II
gene and terminates 1 kb 39 to it. This gene contains 6 exons of
289, 113, 190, 67, 99, and 232 bp with corresponding introns of
80, 120, 161, 107, and 79 bp (Fig. 2A, shaded boxes). DNase
I-hypersensitive sites II and III are located at the 59 end of this
gene, suggesting that they may be involved in its regulation
rather than in that of the IMPDH type II gene.
Additional GenBank cDNA sequences (N51229, H56404, and
H80241) were found to be 100% identical to a 713-bp region
extending 59 from bp 2307 relative to the transcription initia-
tion site of the IMPDH type II gene (21) (Fig. 2A, hatched box).
Similar sequences were found at the same location upstream of
the mouse IMPDH type II coding region. From these data, it
appears that the IMPDH type II gene and another unidentified
gene 59 to it are oriented head-to-head to one another, raising
the possibility that the intergenic region could serve as a bidi-
rectional promoter for both genes. Indeed, our previous results
demonstrated that a 466-bp IMPDH type II promoter CAT
construct was active in both the 59 3 39 and 39 3 59 orienta-
tions, with 7-fold less activity with the latter construct (21).
The identity and function of the proteins encoded by the two
genes closely flanking the IMPDH type II gene are currently
unknown.
Delineation of a Minimal IMPDH Type II Promoter—To de-
fine the boundaries of the promoter region and the relevance of
the specific cis-acting elements that were previously identified
by in vitro footprinting (21), transient transfection assays were
performed with promoter-deletion CAT reporter constructs us-
ing Jurkat T cells. Constructs containing 1027, 461, and 197 bp
of 59-flanking sequence terminating 2 bp upstream of the trans-
lation initiation site were examined for promoter activity and
found to increase CAT activity by 264, 326, and 278-fold over
FIG. 2. DNase I-hypersensitive site analyses of the IMPDH type II gene. A, SacI restriction map of the IMPDH type II gene with the 14
exons denoted by open boxes. The six exons of a downstream gene are represented by shaded boxes and the upstream gene by a hatched box. Nuclei
from the human Jurkat T cell line were either untreated (0 and 37 °C) or treated with increasing concentrations of DNase I (indicated by the
wedges) prior to isolation of genomic DNA, digestion with the restriction enzyme SacI, and Southern blot analysis with an exon 5 (B) or exon 6/7
(C) probe. The 4.8- and 6.4-kb genomic SacI fragments and the positions of the three DNase I-hypersensitive sites are indicated on the schema of
the IMPDH type II gene. Replicated DNA size markers are shown to the left of B.
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pCATBasic, respectively (Fig. 3A and B). The differences in
activities among these constructs in three experiments were
not significant, suggesting that the 197-bp 59-flanking region
(pCATBasic197) contains the elements required for constitu-
tive IMPDH type II promoter activity in this T cell line. How-
ever, a further truncation of 56 bp (pCATBasic141) resulted in
a 72% decrease in promoter activity, indicating that elements
in this region including the overlapping Egr-1/Sp1 site (bp
2143 to 2199) contribute significantly to promoter activity.
The pCATBasic141 construct that accounts for the residual
28% of promoter activity contains binding sites for Sp1, the
ATF/CREB family of transcription factors, and TATA-binding
protein (21).
In Vivo Footprinting—To clarify the in vivo significance of
putative regulatory regions in the promoter, we performed in
vivo footprinting experiments on DNA in resting and activated
peripheral blood T lymphocytes and control and PMA-treated
Jurkat T cells. Two primer sets were used to visualize the
regions between nucleotides 2267 and 214 relative to the ATG
translation initiation site. Fig. 4 identifies a number of contact
regions on both the upper and lower DNA strands of this region
in resting and activated T lymphocytes (Fig. 4, A plus inset and
B, respectively). Alignment of these protein-DNA contact sites
with the promoter sequence (Fig. 4C) identified clustering at
several putative transcription factor binding sites, including
the tandem CRE motifs (CRE(A)(288 to 295) and
CRE(B)(2114 to 2121)), a Sp1 site (2133 to 2142), and an
overlapping Sp1/Egr-1 site (2162 to 2172). In addition, pro-
tein-DNA contacts were observed at a site we have termed the
“palindromic octamer sequence” or POS (CGCATGCG)(2193 to
2200) that does not correspond with any known transcription
factor binding site identified in the Genetics Computer Group
transcription factor data base (Madison, WI). The detected
binding sites were similar, although not identical, in resting
and activated T lymphocytes and control and PMA-treated
Jurkat T cells. The regions of minor change in protein-DNA
contacts observed upon T lymphocyte activation are indicated
by an asterisk in Fig. 4. The upper DNA strand revealed an
enhanced cleavage site at bp 242 adjacent to a consensus
AML1-binding site in resting T lymphocytes (Fig. 4A, lane 4).
Extensions of the footprints at the POS site (bp 2212 and
2215) and TATA box (bp 283) were noted on the lower strand
FIG. 3. Deletion analysis of the IMPDH type II promoter. A, schematic representation of the IMPDH type II gene’s 59-flanking region and
the deletion constructs with the position of transcription factor binding motifs shown relative to the deleted regions and the transcription and
translation initiation sites. B, chloramphenicol acetyltransferase activities of the IMPDH type II deletion constructs transiently transfected into
Jurkat T cells. Values represent the average of duplicate determinations in a single experiment. Data from two additional experiments gave similar
results.
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in T lymphocytes treated with PHA and IL-2 for 24, 48, and
72 h (Fig. 4B, lanes 5–7). In addition, an enhanced cleavage site
was observed in PMA-treated Jurkat T cells and activated T
lymphocytes at the Egr-1/Sp1 site (bp 2162) (Fig. 4B, lanes 2,
5–7). The apparent protection observed on the lower DNA
strand at the bottom of Fig. 4B was not consistently observed in
FIG. 4. In vivo footprinting of protein-DNA interactions in the IMPDH type II promoter by ligation-mediated PCR. In vivo footprint
analysis of the upper (A) and lower (B) strands of the proximal IMPDH type II promoter. Control DNA was methylated in vitro (lane 3), and DNA
from Jurkat T cells in the absence and presence of PMA (lanes 1 and 2) and resting and activated peripheral blood T lymphocytes (lanes 4–7) was
methylated in vivo, as described under “Materials and Methods.” Stimulation of T lymphocytes resulted in increases in [3H]thymidine uptake of
3-, 81-, 192-fold at 24, 48, and 72 h, respectively. IL-2 receptor expression increased from 16% in resting cells to 89, 95, and 98% in the 24-, 48-,
and 72-h activated T lymphocytes. Flow cytometric mean channel fluorescence increased from 21 in the resting T lymphocytes to 140, 361, and 505
in 24-, 48-, and 72-h activated T lymphocytes, respectively. Open arrows indicate protected sites and solid arrows sites of enhanced DNA cleavage
with shorter arrows indicating reduced protection from or enhancement of DNA cleavage. The vertical arrow indicates the location of the
transcription initiation site. C, sequence of the IMPDH type II promoter and summary of the in vivo contact points. Transcription factor binding
sites are indicated by shaded boxes. The experiment was repeated three times on T lymphocytes and twice on Jurkat T cells with similar results.
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these experiments and also could not be detected on longer gel
runs of the upper DNA strand (Fig. 4A). Together these find-
ings suggest that nuclear proteins are pre-bound at the
CRE(A), CRE(B), Sp1, the overlapping Egr-1/Sp1, and the POS
sites in resting T lymphocytes and that PHA and IL-2 stimu-
lations, while perhaps modifying these proteins or causing
additional protein-protein interactions, do not result in major
additional protein-DNA interactions.
Mutational Analysis of Transcription Factor Binding Sites—
Site-directed mutations were engineered at the Egr-1/Sp1,
CRE(B), CRE(A), and AML1 sites, as well as the POS site in the
pCATBasic461 construct (Table I). The double-stranded oligo-
nucleotides containing each mutation were shown not to com-
pete with their respective wild-type sequences for binding of
nuclear factors in EMSA (data not shown). Fig. 5 demonstrates
that mutation of the proximal CRE(A) motif (located between
bp 288 and 295) and the POS site (located between bp 2193
and 2200) reduced promoter activity by 65 and 39% relative to
wild-type activity. Lesser reductions in promoter activity were
observed with the CRE(B) (9%) and Egr-1/Sp1 (25%) muta-
tions. In striking contrast, mutagenesis of both the CRE(A) and
CRE(B) sites resulted in an 83% decrease in CAT activity,
establishing a dominant role for these tandem sites in overall
promoter function. Transfections of these constructs were also
performed using peripheral blood T lymphocytes activated with
PHA and IL-2. However, the levels of CAT activity were ex-
tremely low, and the data could not be interpreted.
The 59-untranslated regions of the human and mouse IM-
PDH type II genes contain identical 17-bp repeats that are
represented once in the human and twice in the mouse gene
(21, 30). This sequence includes an AML1-binding site (31) and
is located at bp 228 to 244 relative to the translation initiation
site in the human gene and at bp 228 to 244 and 245 to 261
in the mouse gene, suggesting an important functional role for
this region in gene expression. To test this hypothesis, muta-
tions were introduced in the AML1-binding site. Mutation of
this site consistently resulted in increased promoter activity
(133%).
Characterization of Nuclear Protein Binding to Individual
cis-Acting Elements by EMSA—To address the role of the in
vivo footprinted elements in the binding of relevant proteins
from nuclear extracts, the transcription factor binding sites
POS, Egr-1/Sp1, CRE(B), CRE(A), and AML1 were analyzed by
EMSA using nuclear extracts derived from resting and acti-
vated peripheral blood T lymphocytes and Jurkat T cells
cultured in the absence and presence of PMA. Competition
experiments with wild-type and corresponding mutant oligo-
nucleotides confirmed the specificity of the interactions at the
sites examined (data not shown). Fig. 6 illustrates that factors
present in resting T lymphocyte nuclear extract bind to the
Egr-1/Sp1, CRE(B), CRE(A), and AML1 sites as well as the
POS site. T lymphocyte nuclear extract obtained at 3 and 6 h
after activation resulted in increased binding of the Egr-1/Sp1
probe (Fig. 6). Binding to the Egr-1/Sp1 oligonucleotide was
slightly reduced at 12 and 24 h of activation, whereas binding
to the CRE(A) and CRE(B) motifs progressively increased up to
24 h of T lymphocyte activation. In addition, binding of nuclear
factors to the consensus CRE(B) element (TGACGTCA) was
found to be consistently stronger than binding to the partial
consensus CRE(A) element (TGACGAAA) (Fig. 6). Nuclear fac-
tor binding to both the POS and the AML1 site demonstrated a
lower mobility shift following T lymphocyte activation (3, 6, 12,
and 24 h), possibly indicating the assembly of a higher-order
complex upon T lymphocyte activation (Fig. 6). These data, in
FIG. 5. Effect of mutagenesis of transcription factor binding
sites on IMPDH type II promoter activity. Transcription factor
binding sites in the 461-bp promoter fragment were subjected to site-
directed mutagenesis using the oligonucleotides outlined in Table I and
wild-type and mutant constructs transfected into Jurkat T cells. Re-
sults are expressed relative to the activity of pCATBasic461 (100%) and
represent the mean and standard deviation of three experiments per-
formed in duplicate.
TABLE I
Sequences of oligonucleotides used for site-directed mutagenesis and gel mobility shift assays
Mutated bases are shown in bold, and transcription factor binding sites are underlined. The sequences represent double-stranded oligonucleo-
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conjunction with the in vivo footprinting results, suggest that T
lymphocyte activation leads to increased protein-DNA binding
activity in nuclear extracts that does not per se coincide with
additional transcription factor binding to the Egr-1/Sp1,
CRE(B), and CRE(A) motifs, while resulting in the formation of
higher order complexes at the POS and AML1 sites. Prelimi-
nary UV cross-linking experiments on the POS site have iden-
tified three proteins in the range of 35–45 kDa in both the
lower and upper protein-DNA complexes (Fig. 6; indicated by
arrows) formed with resting and activated T lymphocyte nu-
clear extract, respectively, suggesting the binding of a multi-
meric protein complex at this site (data not shown).
Binding of nuclear factors in extracts obtained from Jurkat T
cells did not differ from that obtained from resting T lympho-
cytes, whereas extracts obtained from PMA-stimulated Jurkat
T cells exhibited binding patterns at the POS, Egr-1/Sp1,
CRE(B), CRE(A), and AML1 sites similar to that observed in
PHA and IL-2-stimulated T lymphocytes. Only at the overlap-
ping Egr-1/Sp1 site was a higher mobility complex observed
with nuclear extract from PMA-stimulated Jurkat T cells that
was not detected in control Jurkat T cell and resting or acti-
vated T lymphocyte nuclear extract (Fig. 6, indicated by arrow).
EMSA of the Egr-1/Sp1-binding site in the presence of specific
anti-Egr-1 and anti-Sp1 antibodies and nuclear extracts from
control and PMA-treated Jurkat T cells revealed that the low
mobility complex consists of the Sp1 transcription factor, and
the higher mobility complex of the Egr-1 nuclear factor (Fig.
7A). EMSA in the presence of consensus binding sites for Egr-1
and Sp1 further revealed that Egr-1 binding is absent in con-
trol Jurkat T cell nuclear extract and is rapidly induced upon
PMA stimulation (Fig. 7B). The lack of a similar complex in
activated peripheral blood T lymphocytes (Fig. 6) suggests that
the transcription factor Egr-1 is not required for the induced
expression of the IMPDH type II gene in these cells. Further-
more, although the Egr-1/Sp1 site (CCGCCCCCGCC) exhibits
a high degree of identity to a consensus AP2-binding site
(CCGCCCGCG) (32), binding of AP2 was not detected using
supershift analysis (data not shown).
To define the nature of the proteins binding to the CRE sites,
we performed EMSA with the consensus CRE(B) site (Fig. 8) in
the presence of control Jurkat T cell nuclear extract and an
ATF-1 antibody (sc-270X) that recognizes ATF-1-, CREB-1-,
and CREM-1, and ATF-1 (sc-241X)-, ATF-2 (sc-187X)-,
CREB-1, and CREM-1 (sc-440X)-specific antibodies. The con-
sensus CRE(B) site was used in preference to the CRE(A) site
since nuclear factor binding was consistently found to be more
pronounced, whereas the qualitative results obtained with the
CRE(A) and CRE(B) sites were identical using Jurkat T cells
and peripheral blood T lymphocyte nuclear extract. Indeed,
competition experiments between the two CRE sites in the
presence of control Jurkat T cell nuclear extract revealed that
each site completely competes with the other for protein bind-
ing, although the CRE(A) site exhibits a 10-fold lower affinity
than does the CRE(B) site (data not shown). The addition of
antibody sc-270X to Jurkat T cell nuclear extract resulted in a
supershift of the lower complex (Fig. 8, indicated by *). A slight
supershift was observed in the presence of the ATF-1-specific
antibody sc-241X that was visible upon longer exposure (loca-
tion indicated). Incubation with an ATF-2-specific antibody
(sc-187X) resulted in a partial supershift of the CRE(B) com-
plex to an upper band and a lower band that comigrates with
the sc-270X supershift (Fig. 8, indicated by *). Antibodies spe-
cific for CREB-1 (sc-186X) and CREM-1 (sc-440X) did not result
in a supershift of the CRE(B) mobility shift, suggesting that
these factors are not represented in this complex (Fig. 8).
DISCUSSION
The de novo cellular synthesis of guanine nucleotides pro-
vides necessary substrates for both DNA and RNA synthesis
and is required for cell proliferation. Depletion of guanine
nucleotides by a variety of inhibitors of IMPDH enzymatic
activity results in a block in late G1 of the cell cycle that is
reversible with the addition of guanine (12) and also leads to
the induction of differentiation in a wide variety of cell types in
vitro (15–18). Although the specific molecular trigger for G1
arrest is not known, it has been demonstrated that the phos-
phorylation of the Rb protein is inhibited under these condi-
tions,2 establishing the importance of IMPDH enzymatic activ-
ity for cell cycle progression. Inhibitors of IMPDH are also
known to be very effective immunosuppressive agents (19, 20),
and previous studies have documented the requirement for a
10–15-fold increase in IMPDH activity for normal T lympho-
cyte activation (14, 33, 34). Although the IMPDH type II gene
is expressed in all cell types examined to date, the ability to
stimulate peripheral blood T lymphocytes from a resting to
proliferating state and the importance of IMPDH activity for
2 J. Laliberté and B. S. Mitchell, unpublished data.
FIG. 6. Binding of nuclear factors to the POS, Egr-1/Sp1,
CRE(B), CRE(A), and AML1 sites. Nuclear extracts were prepared
from resting T lymphocytes and T lymphocytes stimulated with 1 mg/ml
PHA and 10 units/ml IL-2 for 3, 6, 12, and 24 h and control and PMA (10
ng/ml, 3 h)-treated Jurkat T cells. [3H]Thymidine incorporation into
DNA was determined for the T lymphocytes as a measure of prolifera-
tive activity and was 4-, 2-, 10-, and 9-fold above unstimulated T
lymphocytes for the 3-, 6-, 12-, and 24-h time points, respectively.
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the immune response prompted us to use these non-trans-
formed cells to examine the regulation of IMPDH type II gene
expression in response to growth stimuli. Thus, the objectives
of the present study were first to confirm that the regulation of
IMPDH type II expression was at the level of transcription and
second to define the specific components involved in transcrip-
tional activation.
The finding of identical IMPDH type II mRNA stabilities at
increasing time intervals following T lymphocyte activation
complements our previous data demonstrating a transcrip-
tional response of the transfected IMPDH type II promoter
region to cellular activation with phorbol ester and ionomycin
(21). Chromatin structure analysis identified DNase I-hyper-
sensitive sites both 59 and 39 to the gene that could be involved
in the regulation of IMPDH type II gene expression. However,
more detailed sequence analysis and the demonstration of two
adjacent genes have made interpretation of these data more
difficult. The presumption that the two 39-hypersensitive sites
are associated with the regulation of a relatively small down-
stream gene is a reasonable one, although experimental data
are needed to support this hypothesis. The 59 region of the
IMPDH type II gene (bp 2286 to 146) was independently
isolated and found to contain a CpG island in a study in which
the rat chromosomal protein MeCP2 containing a methyl-CpG
binding domain was used to isolate such sequences (GenBank
Z66268) (35). These data, in conjunction with our prior se-
quence analysis and transient transfection experiments, have
confirmed the regulatory potential of this region and led to the
identification of specific transcription factor binding sites, in-
cluding an Egr-1 site, that were candidate mediators of growth-
related gene expression (21).
Previous studies on the IL-2 promoter in several cell lines
using in vivo footprinting have identified transcription factor
binding sites that are occupied both constitutively and induc-
ibly during T cell activation (36, 37). Our in vivo footprinting
studies of the IMPDH type II promoter have defined five re-
gions of extensive protein-DNA contacts that colocalize with
the following transcription factor binding motifs: tandem CRE
sites, a Sp1 site, an overlapping Egr-1/Sp1 site, and a previ-
ously uncharacterized, extensively protected POS. The pattern
representative of proteins binding to these regions showed
minor modifications at the AML1, Egr-1/Sp1, and POS sites,
suggesting that the increase in IMPDH type II gene tran-
scription in activated T lymphocytes may be related to mod-
ifications of pre-bound transcription factors and/or to the
binding of additional nuclear regulatory protein(s) to pre-
bound proteins at these sites rather than to additional protein-
DNA interactions.
The significance of the Egr-1/Sp1 and POS sites are further
established by deletion experiments, where removal of a 56-bp
region containing these sites reduced promoter activity by more
than 70%, as well as by the site-directed mutagenesis data. The
POS site (CGCATGCG) has not been previously identified as
important in nuclear protein binding assays according to anal-
ysis of defined transcription factor binding sites as contained in
the Genetics Computer Group data base (Madison, WI). EMSA
analysis of the sequence demonstrated a shift in both resting T
lymphocytes and Jurkat T cells and the formation of a higher
order complex upon PHA and IL-2 stimulation and PMA treat-
ment, respectively. These data indicate that this sequence
clearly binds nuclear protein in resting T lymphocytes and
further suggests that non-DNA binding accessory protein(s)
may bind following T lymphocyte activation and as a conse-
quence of PMA treatment of Jurkat T cells. UV cross-linking
FIG. 7. Characterization of Egr-1
and Sp1 binding to the overlapping
consensus Egr-1/Sp1 sites. EMSA and
supershift assays were performed using
nuclear extracts from control and PMA
(10 ng/ml, 3 h) -treated Jurkat T cells. A,
transcription factor binding to the wild-
type IMPDH type II oligonucleotide (GC-
CAGCTCCGCCCCCGCCGCAGCGAG) in
the absence and presence of anti-Sp1 and
anti-Egr-1 antibodies. B, transcription
factor binding to consensus Sp1 (CTCGC-
CCCGCCCCGATCGAAT) and Egr-1
(TCGCCCCCGCTCGCCCCCGCTGGA-
TCC) sites in the absence and presence of
anti-Sp1 and anti-Egr-1 antibodies. The
identity of EMSA complexes for A and B
are indicated on the right side of B.
FIG. 8. Identification of the nuclear factors that bind to the
consensus CRE(B) element. Mobility shift assays were performed
with Jurkat T cell nuclear extract in the absence or presence of the
antibody ATF-1 (sc-270X; recognizes ATF-1, CREB-1, and CREM-1)
and specific antibodies for ATF-2 (sc-187X), ATF-1 (sc-241X), CREB-1
(sc-186X), and CREM-1 (sc-440X). Identical results were obtained with
the CRE(A) site. The identity of EMSA supershift complexes are indi-
cated on the right side of the panel.
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experiments at this site have consistently identified three dis-
tinct proteins in the range of 35–45 kDa in the high mobility
complex that predominates in resting T lymphocytes (data not
shown). No additional proteins were identified in the low mo-
bility complex observed with stimulated T lymphocyte nuclear
extract, although a slight extension of the POS footprint upon
PHA and IL-2 stimulation suggests that such binding may
occur in vivo. Despite the fact that the sequence surrounding
and including the POS site (ATACGCATGCG) exhibits some
sequence similarity to the Oct-1 and Oct-2 transcription factor
binding sites (ATTTGCAT), the Oct-1 and Oct-2 proteins are of
significantly higher molecular mass (90 and 60 kDa, respec-
tively) than those observed in our UV cross-linking experi-
ments (38, 39). The further characterization of the proteins
binding to the POS site may lead to the identification of a novel
transcription factor that will be highly relevant to our overall
understanding of IMPDH type II gene transcription.
The overlapping Egr-1/Sp1-binding site binds Sp1 in un-
stimulated Jurkat T cell nuclear extract and inducibly binds
Egr-1 after phorbol ester treatment. However, no equivalent
shift in electrophoretic mobility was found in PHA and IL-2-
stimulated T lymphocytes, arguing that Egr-1 does not play a
role in the up-regulation of IMPDH type II gene expression
under these conditions. Although Egr-1 is expressed in PMA-
treated Jurkat T cell nuclear extract and can bind to its con-
sensus site in EMSA assays, the in vivo footprinting results do
not reveal a distinguishable difference in the contact sites at
the overlapping Egr-1/Sp1 site between stimulated Jurkat T
cells and their T lymphocyte counterparts. These findings sug-
gest that Egr-1 is unable to compete for Sp1 binding at this site
in intact cells. Although Egr-1 has previously been shown to be
expressed in PMA-treated Jurkat T cells (40), as well as tran-
siently in rat T lymphocytes following IL-2 or concanavalin A
treatment (41), and has been implicated in the transcriptional
regulation of several genes including IL-2 and thymidine ki-
nase (40, 42), the recent demonstration that Egr-1-deficient
mice, although deficient in luteinizing hormone, have no major
developmental defects (43) suggests that Egr-1 is not important
for the regulation of growth-related genes such as IMPDH type
II. Based on our findings, we conclude that Sp1 and not Egr-1
binding at the Egr-1/Sp1 site contributes to IMPDH type II
gene expression.
Mutation of the proximal CRE(A) motif was associated with
a profound impairment of promoter activity, whereas loss of the
CRE(B) site with identical protein binding properties on EMSA
had little effect. However, simultaneous mutation of the
CRE(A) and CRE(B) sites resulted in an 83% decrease in pro-
moter activity, demonstrating an important role of the tandem
elements for overall promoter function. This functional impor-
tance is further supported by the observation that the CRE(A)
and CRE(B) sites are conserved at the same location relative to
the transcription start site in the mouse IMPDH type II pro-
moter.3 Supershift analysis of both CRE motifs identified
ATF-2 as the predominant protein that binds from both resting
and activated T lymphocyte and Jurkat T cell nuclear extracts,
with evidence that ATF-1 and/or another unidentified member
of the ATF/CRE family may also bind. Although, we have been
unable to demonstrate a quantitative increase in the levels of
ATF-2 (70 kDa) after T lymphocyte activation using Western
blot analysis (data not shown), ATF-2 is the most plausible
candidate for mediating both the basal and inducible transac-
tivation of the IMPDH type II gene. ATF-2 has recently been
shown to be involved in the expression of the tumor necrosis
factor a gene in stimulated T cells (44). In addition, transacti-
vation by the human T cell leukemia virus Tax (45) and ade-
novirus E1A proteins (46, 47) has been attributed to ATF-2.
Finally, as a target of the JNK signal transduction pathway
(48), this transcription factor may be integrally involved in
regulating the expression of a number of genes important for
cell proliferation and transformation.
In conclusion, our data provide evidence that ATF-2, Sp1,
and a POS-binding protein are important for the regulation of
IMPDH type II gene expression in vivo in peripheral blood T
lymphocytes and, by extension, in the provision of guanine
nucleotides required for cell growth. The transcriptional up-
regulation of the IMPDH type II gene does not appear to
require major additional protein binding directly to the core
promoter region but may well involve events such as secondary
protein-protein interactions and/or post-translational modifica-
tions of pre-bound transcription factors. The identification of
the novel POS should lead to its recognition in the sequences of
other promoters, and further delineation of the nature and
availability of proteins binding to it will enhance our under-
standing of the regulation of IMPDH type II gene expression.
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